This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/kegg-compound/
n30http://linked.opendata.cz/resource/AHFS/
n20http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/pubchem-substance/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/iuphar/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/drugbank/
n8http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/guide-to-pharmacology/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/chemspider/
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n31http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00665/identifier/chebi/
n16http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/atc/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00665
rdf:type
n5:Drug
n5:description
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
n5:dosage
n14:271B3E9A-363D-11E5-9242-09173F13E4C5 n14:271B3E9B-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Kassouf W, Tanguay S, Aprikian AG: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003 May;169(5):1742-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12686822 # Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J: Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol. 2006 Jun;13(3):81-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17576447
n5:group
approved
n5:halfLife
38.0-59.1 hours
n5:indication
For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).
n5:manufacturer
n20:271B3E98-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00665 n28:DB00665
dcterms:title
Nilutamide
adms:identifier
n11:Nilutamide n15:4337 n17:DB00665 n18:7573 n19:2864 n21:C08164 n22:2864 n23:PA450632 n24:4493 n25:D00965 n27:0088-1111-14 n29:46505381
n5:mechanismOfAction
Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.
n5:packager
n20:271B3E97-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
Nilutamide is extensively metabolized andless than 2% of the drug is excreted unchanged in urine after 5 days. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days.
n5:synonym
Nilutamide Nilutamida Nilandron 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin Nilutamidum
n5:toxicity
Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
n3:hasAHFSCode
n30:10-00-00
n5:foodInteraction
Take before breakfast. Avoid alcohol.
foaf:page
n13:nilutamide.html n16:nil1294.shtml n31:nilutam.htm
n5:IUPAC-Name
n6:271B3EA0-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B3EA6-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B3EA5-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B3EA2-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B3EA3-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B3EA4-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B3E9E-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B3E9F-363D-11E5-9242-09173F13E4C5 n6:271B3EB6-363D-11E5-9242-09173F13E4C5 n6:271B3E9C-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B3E9D-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n4:L02BB02
n5:H-Bond-Acceptor-Count
n6:271B3EAC-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B3EAD-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B3EA7-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B3EA8-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B3EAA-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B3EA9-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B3EAB-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
63612-50-0
n5:category
n5:containedIn
n9:271B3E99-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B3EB2-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B3EB4-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B3EB5-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B3EB1-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B3EB0-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B3EB3-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B3EA1-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B3EAE-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B3EAF-363D-11E5-9242-09173F13E4C5